Nascent Biotech, Inc., founded in North Palm Beach, FL, is a biotechnology company dedicated to developing and delivering human antibodies for cancer treatment. Their core mission is to innovate and advance cancer therapies, with a vision to improve patient outcomes through cutting-edge biotechnological solutions. The company's primary product is Pritumumab, an antibody designed to target and treat various forms of cancer. Nascent Biotech focuses on the clinical-stage development of these therapies, aiming to address unmet medical needs in oncology.

Notable affiliations include collaborations with Manhattan BioSolutions to explore antibody-drug conjugates. Key achievements include progressing to pivotal Phase II research and receiving positive analyst opinions. The company has garnered attention for its innovative approach to cancer treatment, contributing significantly to the biotech field with its specialized antibody therapies. Nascent Biotech's impact lies in its potential to revolutionize cancer treatment, offering new hope to patients through advanced biotechnological advancements.